The future is looking bright for bladder cancer, with many clinical studies of new therapeutic options underway. Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Kirollos Hanna, PharmD, BCOP, BCPS, of the University of Minnesota Medical Center, Minneapolis, MN, provides an exciting overview of current clinical trials and discusses the challenges of treating second-line metastatic urothelial cancer. Just some of the exciting new drugs discussed include ramucirumab, cabozantinib and tremelimumab.
Looking towards the future: what is in store for the treatment of bladder cancer?
